- Business
- China Meheco Group Co., Ltd. (600056.SS) engages primarily in the pharmaceutical healthcare sector, operating an integrated business model spanning research and development, cultivation and processing of herbal medicines, manufacturing, distribution, logistics, international trading, academic promotion, and technical services for pharmaceuticals and medical devices; its core products encompass bulk pharmaceutical chemicals via antibiotic fermentation and chemical synthesis, tablets, injections, and capsules; antibiotics; medicines treating cardio-cerebrovascular diseases, chronic conditions, and diabetes; antiviral and anti-infectious agents; gastrointestinal drugs; non-steroidal anti-inflammatory drugs; anti-allergic agents; specialty botanicals; western medicine preparations; Chinese patent medicines and herbal pieces; medical equipment and supplies; biological products; chemical raw materials; and nutritional healthcare products, with additional operations in planting, processing, warehousing, and transporting herbs such as ginseng, licorice, ephedra, rhubarb, astragalus membranaceus, scutellaria baicalensis, and fennel. The company, founded in 1983 as China National Medicines and Health Products Import and Export Corporation and headquartered at No. 18 Guangming Zhongjie, Beijing, China, functions as the sole platform under controlling shareholder China General Technology (Group) Holding Co., Ltd. for integrating pharmaceutical and medical device manufacturing and marketing, with business segments including industrial pharmaceuticals (chemical preparations, bulk drugs, biologicals, Chinese patent medicines), commercial pharmaceuticals (wholesale and distribution of drugs and devices), and international trading (exporting natural medicines, pharmaceutical chemicals, equipment, and health products); it serves healthcare institutions, retail pharmacies, and global markets primarily in China and internationally. Recent developments feature the November 2024 agreement to acquire the remaining 40% stake in Genertec Meheco Liaoning Co., Ltd. from Li Qiang for CNY 68.4 million in cash, achieving 100% ownership upon completion subject to shareholder and board approvals, alongside ongoing strategic expansions in medicine trading via equity investments, capital increases, and industry chain integration under the Healthy China Initiative.